Navigation Links
ASCO releases studies from upcoming annual meeting
Date:5/17/2012

ALEXANDRIA, Va. The American Society of Clinical Oncology (ASCO) today highlighted five studies in a press briefing from among more than 4,500 abstracts publicly posted online at abstract.asco.org in advance of ASCO's 47th Annual Meeting.

Plenary, late-breaking and other major studies will be released in on-site press conferences at the Annual Meeting to be held June 1-5, 2012, at McCormick Place in Chicago, Ill. The meeting, which will feature the theme Collaborating to Conquer Cancer, is expected to draw approximately 30,000 cancer specialists from around the world.

"Nearly 50 years into the era of modern oncology, we can clearly see the fruits of our research investments," said Michael Link, MD, President of ASCO. "Findings to be presented at ASCO's Annual Meeting are part of the latest chapter in the history of progress against cancer. Today's studies demonstrate improvements in precision medicine that identify and exploit cancer's genetic weak spots to halt tumor growth and in some cases eradicate disease. Other studies give us valuable new tools and information to lessen the short- and long-term side effects of cancer treatment for our patients."

Studies highlighted in today's press briefing include:

  • In early study, crizotinib induces strong, long-lasting responses in aggressive pediatric cancers: Phase I study reports that crizotinib (Xalkori) an oral drug that targets genetic abnormalities in the ALK gene stalled tumor growth and, in some cases, eliminated all signs of cancer in select children with neuroblastoma, anaplastic large cell lymphoma or inflammatory myofibroblastic tumors, cancers commonly driven by ALK gene abnormalities.

  • Combination of two molecularly targeted oral drugs show promise for advanced melanoma with BRAF mutations: Results from an early-phase trial show that combination therapy with two investigational targeted drugs the BRAF inhibitor dabrafenib and the MEK inhibit
    '/>"/>

Contact: Susie Tappouni
susie.tappouni@asco.org
571-483-1355
American Society of Clinical Oncology
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Markle releases new resources for health information sharing implementation
2. AGA releases first independently developed ABIM-approved Practice Improvement Module in GI
3. American College of Physicians releases new colorectal cancer screening guidance statement
4. Presidents Bioethics Commission releases report on human subjects protection
5. Society for Integrative Oncology releases findings presented at annual meeting
6. Health Information Technology and Patient Safety - IOM report releases Nov. 10
7. Federal government releases environmental, health, and safety research strategy for nanotechnology
8. NNI releases 4 workshop reports from the nanoEHS Series
9. ASCO releases studies from upcoming annual meeting
10. AMP releases statement on diagnostics in drug labels
11. IADR/AADR Journal of Dental Research releases studies on oral health inequalities in older people
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Dr. James C. Wittig, Chief of Orthopedic ... Division of the John Theurer Cancer Center at Hackensack ... one of the top 13 Orthopedic Oncologists in the ... is one of approximately 125 surgeons in America who ... surveying thought leaders in the field of Oncology. Dr. ...
(Date:5/21/2013)... Chicago, IL (PRWEB) May 21, 2013 ... information on the site for patients taking the blood ... drug may be at more risk of death when ... , DrugRisks was created to improve the safety of ... warnings, recalls, studies and legal news. Visitors can see ...
(Date:5/20/2013)... The India Network Foundation, a ... insurance, announces a new pre-existing condition coverage plan: ... the years, India Network members have requested a ... maximums, and duration. The Platinum Comprehensive Plan is ... the valuable coverage and benefits of a PPO ...
(Date:5/20/2013)... Southfield, Michigan (PRWEB) May 21, 2013 This ... National Dog Bite Prevention Week (May 19th-May 25th) is an ... dog bite attacks and by encouraging dog owners to properly ... a dog. , Michigan dog bite lawyers at ... animal attacks in cases throughout Michigan. The personal injury law ...
(Date:5/20/2013)... May 20, 2013 When people ... not always to become a celebrity. New Jersey ... 2013 ABC News report (“Chris Christie Says Lap ... clear that the surgery was not done so ... gain celebrity status as a former lap band ...
Breaking Medicine News(10 mins):Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 2Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 3Health News:DrugRisks Update: New Study Warns of Pradaxa Brain Bleeding 2Health News:Indian Network announces Platinum Comprehensive Visitor Health Insurance Plan with Pre-existing Condition Choices for Visitors on Short Term Trip to the United States 2Health News:Indian Network announces Platinum Comprehensive Visitor Health Insurance Plan with Pre-existing Condition Choices for Visitors on Short Term Trip to the United States 3Health News:Buckfire & Buckfire, P.C. Dog Bite Lawyers in Michigan Discuss National Dog Bite Prevention Week 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 3
... Feb. 4 The Carol Milgard Breast Center was awarded ... (FDA) for adhering to the most rigorous quality and safety standards ... "All Items in Compliance" rating from the FDA is exceptional because ... high quality standard.   , John Peixotto , M.D., a ...
... American Society for Radiation Oncology (ASTRO) and the ... guidelines for image guided radiation therapy (IGRT) and ... issue of the International Journal of Radiation ... guidelines were released as educational tools to assist ...
... reveals new way to repair damage with natural tissue ... nanofiber gel that promotes cartilage growth in joints has ... injected into the damaged joint and stimulates bone marrow ... for expensive growth factors. No current therapy can do ...
... , ... Foundation and Shands HealthCare announce today that they have ... needs assessment for a Gainesville -based children,s hospital. The assessment began ... , "We are confident that the experts at Sg2 will ...
... , NEW YORK , Feb. 4 ... announced more than $2.8 million in awards for ... PD. The development of biomarkers is of critical importance to ... scientists and clinicians to more accurately identify appropriate subjects for ...
... February 4, 2010 -- Giving smokers information about their ... to quit smoking, according to a paper published in ... "Personalized risk assessment has been the mainstay of ... mortality reduction over the last decade," said Dr. Robert ...
Cached Medicine News:Health News:Carol Milgard Breast Center Awarded Highest Government Rating for Mammography Sites 2Health News:ASTRO, ACR issue IGRT, SBRT guidelines 2Health News:Nanofiber Gel May Spur Growth of New Knee Cartilage 2Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 2Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 3Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 2Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 3Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 4Health News:Tests showing smokers their individual risk of future disease will help them quit, says paper 2Health News:Tests showing smokers their individual risk of future disease will help them quit, says paper 3
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ...   Summary ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, ... secondary analysis of its double-blind, randomized, controlled Phase ... a gene therapy product designed to deliver the ... analysis identified a more robust response to CERE-120 ... to treatment relative to those diagnosed 10 years ...
(Date:5/21/2013)... Calif. , May 21, 2013 /PRNewswire/ ... ), a specialty pharmaceutical company focused on ... for the treatment of acute and breakthrough ... in a placebo-controlled Phase 3 study of ... analgesia) System (NanoTab System), the primary efficacy ...
Breaking Medicine Technology:Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
... RA Signs and Symptoms Compared to Placebo, ... (Nasdaq: TRBN ) today announced preliminary ... double-blind, placebo-controlled, multicenter,clinical trial of its TRU-015 ... indicated that Trubion,s TRU-015 product candidate, at,well-tolerated ...
... Calif., Sept. 10 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... antibodies for the treatment of cancer and,hepatitis C ... submitted a,clinical protocol with the Drug Controller General ... safety and efficacy trial of bavituximab in combination,with ...
Cached Medicine Technology:Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 2Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 3Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 4Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 5Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 2Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 3Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 4
Anorectal Stylet for LATITUDE® Air-Charged Catheter...
Omnilink Adapter Cable for LATITUDE® Air-Charged Catheter...
Solid State Manometry Catheter Accessory., ,Manometric calibrators are required for calibration of solid state catheters., ,Each type of catheter requires a unique calibrator....
... The ITREL 3 is a battery ... in the U.S., ,Enterra™ Therapy is ... and vomiting associated with gastroparesis when conventional ... of symptons for diabetic or idiopathic patients., ...
Medicine Products: